Cancer Center Clínica Universidad de Navarra (CCUN)
Centro clínico de la Universidad de Navarra
![Foto de Cancer Center Clínica Universidad de Navarra (CCUN)](/img/uploaded/C185D7383C9859310EFAE5D78F321270.jpg)
![Foto de Policlinico S.Orsola-Malpighi](/img/noimage_org.png)
Policlinico S.Orsola-Malpighi
Bolonia, ItaliaPublicaciones en colaboración con investigadores/as de Policlinico S.Orsola-Malpighi (73)
2024
-
Corrigendum to “European guidelines for the diagnosis, treatment and follow-up of breast lesions with uncertain malignant potential (B3 lesions) developed jointly by EUSOMA, EUSOBI, ESP (BWG) and ESSO” [Eur J Surg Oncol 50 (1) (January 2024) 107292] (European Journal of Surgical Oncology (2024) 50(1), (S0748798323009307), (10.1016/j.ejso.2023.107292))
European Journal of Surgical Oncology
-
EUSOMA quality indicators for non-metastatic breast cancer: An update
European Journal of Cancer, Vol. 198
-
European guidelines for the diagnosis, treatment and follow-up of breast lesions with uncertain malignant potential (B3 lesions) developed jointly by EUSOMA, EUSOBI, ESP (BWG) and ESSO
European Journal of Surgical Oncology, Vol. 50, Núm. 1
-
Factors Impacting Survival After Transarterial Radioembolization in Patients with Unresectable Intrahepatic Cholangiocarcinoma: A Combined Analysis of the Prospective CIRT Studies
CardioVascular and Interventional Radiology, Vol. 47, Núm. 3, pp. 310-324
-
Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial
The Lancet Haematology, Vol. 11, Núm. 3, pp. e216-e227
-
International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma
The Lancet Oncology, Vol. 25, Núm. 5, pp. e205-e216
-
Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040
Annals of Oncology, Vol. 35, Núm. 6, pp. 537-548
-
Plain language summary of the KarMMa-3 study of ide-cel or standard of care regimens in people with relapsed or refractory multiple myeloma
Future Oncology
-
Recurrence and tumor-related death after resection of hepatocellular carcinoma in patients with metabolic syndrome
JHEP Reports, Vol. 6, Núm. 7
-
Robotic Versus Laparoscopic Liver Resection in Various Settings: An International Multicenter Propensity Score Matched Study of 10.075 Patients
Annals of Surgery, Vol. 280, Núm. 1, pp. 108-117
-
Treatment and outcomes in breast cancer patients: A cross section study from the EUSOMA breast centre network
European Journal of Cancer, Vol. 196
-
Trends in the characteristics and perioperative outcomes of patients undergoing laparoscopic and open resections for benign liver lesions: An international multicenter retrospective cohort study of 845 patients
HPB, Vol. 26, Núm. 2, pp. 188-202
2023
-
Alternative forms of portal vein revascularization in liver transplant recipients with complex portal vein thrombosis
Journal of Hepatology, Vol. 78, Núm. 4, pp. 794-804
-
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
New England Journal of Medicine, Vol. 389, Núm. 4, pp. 335-347
-
Correction: “The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms” Leukemia. 2022 Jul;36(7):1720–1748 (Leukemia, (2022), 36, 7, (1720-1748), 10.1038/s41375-022-01620-2)
Leukemia
-
European Association of Nuclear Medicine (EANM) Focus 4 consensus recommendations: molecular imaging and therapy in haematological tumours
The Lancet Haematology, Vol. 10, Núm. 5, pp. e367-e381
-
Factors impacting survival after transarterial radioembolization in patients with hepatocellular carcinoma: Results from the prospective CIRT study
JHEP Reports, Vol. 5, Núm. 2
-
Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma.
New England Journal of Medicine, Vol. 388, Núm. 11, pp. 1002-1014
-
Impact of Elotuzumab Plus Pomalidomide/Dexamethasone on Health-related Quality of Life for Patients with Relapsed/Refractory Multiple Myeloma: Final Data from the Phase 2 ELOQUENT-3 Trial
HemaSphere, Vol. 7, Núm. 3, pp. E843
-
MRD dynamics during maintenance for improved prognostication of 1280 patients with myeloma in the TOURMALINE-MM3 and -MM4 trials
Blood, Vol. 141, Núm. 6, pp. 579-591